In an effort to attract international life science funds to Québec, the Fonds de solidarité FTQ is investing €10.5m (C$14.3 million) in the Netherlands-based Forbion III fund.
Led by Sander van Deventer, Managing Partner, Forbion Capital Partners is a dedicated Life Sciences venture capital firm with offices in Naarden, The Netherlands, Munich, Germany and representation in Boston, US.
The firm invests in life sciences companies in drug discovery & development as well as medical device companies addressing unmet medical needs. Investments include Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda (ACOR), Fovea, Insmed (INSM), PanGenetics, Argenta Discovery, BioVex, Pathway Medical, CircuLite, bluebird bio (BLUE), uniQure (QURE), Argos (ARGS), arGEN-X (ARGX.BR), Santaris and PneumRx.
Forbion also operates a joint venture with BioGeneration Ventures, who manages two separate seed and early stage funds focused on Benelux. Including the new fund FCF III, Forbion manages EUR 540M across 5 funds.
This injection completes the Fonds de solidarité FTQ’s current cycle of investments in life science funds. Other recent investments include:
– Lumira Capital II,
– Sanderling VII,
– Versant V and
– CTI Life Sciences Fund II.
In the following years, the Fonds will shift the focus to direct investments in such entities as GlyPharma, PRCL Research, Zymeworks, Esperas, enGene and Thrasos.